Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Mar 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Identifying drugs that reverse disease-associated transcriptomic features has been widely explored for drug repurposing, but its potential for de novo drug discovery remains underexplored. Here, we present gene expression profile predictor on chemical structures (GPS), a deep-learning-based drug discovery platform, guided by transcriptomic features, that screens large compound libraries and optimi
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。